Drug Device Combination Market Driven by Growing Awareness of Efficacy
Market Overview:
The
global Drug Device Combination Market
is expected to exhibit a strong 11.4% CAGR over the forecast period from
2018 to 2023, according to the latest research report from Market
Research Future (MRFR).
Competitive Analysis:
·
Zimmer Holding Inc
·
Wright Medical Group Inc
·
Stryker Corporation
·
St. Jude Medical Inc
·
Smith & Nephew plc
·
Covidien Ltd
·
Cook Critical Care Inc
·
C.R. Bard Inc
·
Boston Scientific Corporation
·
Biotronik
·
Biometrix Medical
Segmentation:
·
The global drug device combination market is
segmented based on product, application, end use, and region.
·
By product, the global drug device combination market is segmented
into catheters, advanced wound care products, and others. The catheter segment
is sub-segmented into antimicrobial catheters, urological catheters, cardiovascular
catheters, oximetry catheters, thermodilution catheters, wound drainage
catheters, and others.
·
By
application, the global drug device combination market is segmented into coronary
angioplasty, tachycardia management, non-cardiovascular treatments, peripheral
arterial disease, bone treatments, antimicrobial applications, wound care,
ophthalmic treatments, and others.
·
By end use,
the global drug device combination market is segmented into hospitals and
clinics, ambulatory centers, academic and research organizations, and others. Hospitals
and clinics are likely to remain the leading end use segment over the forecast
period due to their growing demand for drug device combinations.
Regional Analysis:
The
Americas held the major share in the global drug device combination market in
2017 and are likely to emerge as the leading revenue generator over the
forecast period till 2023, according to MRFR. The Americas drug device
combination market is mainly driven by the growing awareness about the
effectiveness of drug device combinations in North America, mainly the U.S. North
America is likely to remain the leading player in the global drug device
combination market over the forecast period, with the U.S. emerging as the
leading country-level market. The growing drug device combination market in
North America is mainly fed by the growing awareness about the efficacy of drug
device combinations in the region.
The growing prevalence of
tachycardia and coronary issues in North America is likely to remain a key
driver for the drug device combination market in the region over the forecast period.
Rising consumption of junk food and increasing prevalence of sedentary
lifestyles have driven the prevalence of cardiac issues in North America. The
increasing healthcare expenditure in the region means that companies and major
players are free to explore all possible options before settling on the best
one. This has led to the creation of a strong research sector in the region,
which has driven successful initiation of a number of drug therapies as well as
devices into the healthcare sector in recent years. This is likely to remain a
major driver for the North America drug device combination market over the forecast
period.
Comments
Post a Comment